TY - JOUR
T1 - Complications Following Percutaneous Mitral Valve Repair
AU - Gheorghe, Livia
AU - Ielasi, Alfonso
AU - Rensing, Benno J.W.M.
AU - Eefting, Frank D.
AU - Timmers, Leo
AU - Latib, Azeem
AU - Swaans, Martin J.
N1 - Publisher Copyright:
© Copyright © 2019 Gheorghe, Ielasi, Rensing, Eefting, Timmers, Latib and Swaans.
PY - 2019/10/18
Y1 - 2019/10/18
N2 - Mitral valve disease affects more than 4 million people in the United States and it is the second most prevalent valvulopathy in Europe. The gold standard of treatment in these patients is surgical repair or mitral valve replacement. In the last decade, numerous transcatheter therapies have been developed to overcome the increased number of subjects with symptomatic severe mitral regurgitation and high surgical risk. The Mitraclip (Abbott Vascular, Menlo Park, CA), PASCAL (Edwards Lifesciences, Irvine, CA, USA), the Carillon™ Mitral Contour System™ (Cardiac Dimension Inc., Kirkland, WA, USA), the Mitralign™ (Mitralign, Tewksbury, Massachusetts), and the Cardioband (Edwards Lifesciences, Irvine, CA) are the principal percutaneous devices for mitral valve repair. We present an evidence-based clinical update that provides an overview of these technologies and their potential complications.
AB - Mitral valve disease affects more than 4 million people in the United States and it is the second most prevalent valvulopathy in Europe. The gold standard of treatment in these patients is surgical repair or mitral valve replacement. In the last decade, numerous transcatheter therapies have been developed to overcome the increased number of subjects with symptomatic severe mitral regurgitation and high surgical risk. The Mitraclip (Abbott Vascular, Menlo Park, CA), PASCAL (Edwards Lifesciences, Irvine, CA, USA), the Carillon™ Mitral Contour System™ (Cardiac Dimension Inc., Kirkland, WA, USA), the Mitralign™ (Mitralign, Tewksbury, Massachusetts), and the Cardioband (Edwards Lifesciences, Irvine, CA) are the principal percutaneous devices for mitral valve repair. We present an evidence-based clinical update that provides an overview of these technologies and their potential complications.
KW - Cardioband
KW - Carillon device
KW - MitraClip®
KW - Mitralign
KW - complications
KW - mitral valve (MV) repair
KW - transcatheter interventions
UR - http://www.scopus.com/inward/record.url?scp=85079433278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079433278&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2019.00146
DO - 10.3389/fcvm.2019.00146
M3 - Review article
AN - SCOPUS:85079433278
SN - 2297-055X
VL - 6
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
M1 - 146
ER -